Anton Rx Report

The FDA recently approved a new form of therapy for ALS. Normally, a new form is not big news, but, for this therapy, it may

The FDA recently approved the fourth pegfilgrastim biosimilar referencing Neulasta, Fylnetra (pegfilgrastim-pbbk) from Amneal Pharmaceuticals. Fylnetra is a leukocyte growth factor indicated to decrease the

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely

Now here’s something ya don’t see every day!A drug approved within the last year being yanked from the market. This week, the FDA pulled approval

Back in February we sent a report detailing an innovative network approach to alternate site / home infusion and it seems to be a topic

The FDA this week issued final guidance related to the importation of drugs from Canada. Importation was passed late last year but many questions remained unresolved. 

A significant number of specialty pharmacies have contracted as a 340b dispensing pharmacy often for multiple ‘program eligible’ hospitals. As most know, manufacturers have recently

Earlier this month the FDA approved an ORAL specialty therapy, Cuvrior (trientine tetrahydrochloride) from Orphalan SA, for the treatment of adults with stable Wilson’s disease

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy via limited distribution (LD). However, the press releases

We’ve written about the emergence of telehealth services for the past several years. As then, we continue to see positive uptake, albeit much slower than